Stephen joined Karus as CSO in 2008, and in 2017 was appointed COO. He is the founding scientist of Karus’s PI3K-p110β/δ and HDAC6 therapeutic programs. He has a successful track record, gained over 23 years, in the design and development of molecular-targeted therapeutics for cancer, immune-inflammation and metabolic diseases. Prior to Karus, he held R&D management positions in UK and North American biotech, at Chiroscience (UK), BiochemPharma (Canada), Tularik (USA), CRUK, and Piramed (UK) where he directed the PI3K-p110α and p110δ programs, designing and leading the preclinical development of Pictilisib.
Stephen obtained his BSc and PhD in Chemistry from the University of Liverpool. He and is a recognized opinion leader in the PI3K and HDAC arenas, has published extensively, and was appointed a Fellow of the Royal Society of Chemistry in 2007. In 2014 he was appointed an Honorary Professor, Cancer Sciences, at the University of Manchester.